Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
Recruiting
Observational Study
Persistent COVID Condition
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400 (estimated)
- Sponsor
- Instituto de Investigación Biomédica de Salamanca · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.
The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults ≥18 years old.
* Confirmed previous SARS-CoV-2 infection.
* Diagnosis of long COVID according to WHO criteria.
* Participation in the baseline BioICOPER study.
* Signed informed consent for re-evaluation.
Exclusion Criteria:
* Acute illness preventing participation.
*…
Contacts